Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10564
Shown on this page
12
Current sort
Recently updated
Location scope
Cincinnati, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Cincinnati, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 589–600 of 10,564 matching trials in Cincinnati, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

NCT04797104
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Recruiting No phase listed Observational

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

NCT07335523
View directory record Official record
Conditions
Exocrine Pancreatic Insuficiency
Interventions
Fecal Fat
Diagnostic Test
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About a Vaccine Against E Coli in Healthy Adults

NCT07122986
View directory record Official record
Conditions
Healthy Participants
Interventions
E coli vaccine 1 Dose A, E coli vaccine 1 Dose B, E coli vaccine 2, E coli vaccine 3, E coli Vaccine 4 Dose A, E coli Vaccine 4 Dose B, E coli Vaccine 4 Dose C, E coli Vaccine 5 Dose A, E coli Vaccine 5 Dose B, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
11
States / cities
Anaheim, California • Lake Forest, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Recruiting Phase 3 Interventional

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant with Ranibizumab 100 mg/mL
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Suspended Phase 2Phase 3 Interventional

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

NCT05691478
View directory record Official record
Conditions
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions
Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
1,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

NCT01362803
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1, Neurofibroma, Plexiform
Interventions
AZD6244
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2032
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Recruiting Phase 2 Interventional

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Panitumumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Duarte, California • Santa Monica, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879
View directory record Official record
Conditions
Proteinuric Kidney Disease
Interventions
VX-147, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
10 Years to 65 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
223
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Not yet recruiting Phase 3 Interventional

Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction

NCT07880743
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Pain, Postoperative
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Dave Bernholt
Other
Eligibility
14 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Skokie, Illinois • St Louis, Missouri • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 13, 2026, 2:37 PM EST
Recruiting No phase listed Observational

Real World Prostate Cancer Registry

NCT06355336
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Cincinnati Cancer Advisors
Network
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 13, 2026, 2:37 PM EST